Identification of a leukemia-initiating stem cell in human mast cell leukemia.

Abstract:

:Mast cell leukemia (MCL) is a highly fatal malignancy characterized by devastating expansion of immature mast cells in various organs. Although considered a stem cell disease, little is known about MCL-propagating neoplastic stem cells. We here describe that leukemic stem cells (LSCs) in MCL reside within a CD34+/CD38- fraction of the clone. Whereas highly purified CD34+/CD38─ cells engrafted NSGhSCF mice with fully manifesting MCL, no MCL was produced by CD34+/CD38+ progenitors or the bulk of KIT+/CD34- mast cells. CD34+/CD38- MCL cells invariably expressed CD13 and CD133, and often also IL-1RAP, but did not express CD25, CD26 or CLL-1. CD34+/CD38- MCL cells also displayed several surface targets, including CD33, which was homogenously expressed on MCL LSCs in all cases, and the D816V mutant form of KIT. Although CD34+/CD38- cells were resistant against single drugs, exposure to combinations of CD33-targeting and KIT-targeting drugs resulted in LSC-depletion and markedly reduced engraftment in NSGhSCF mice. Together, MCL LSCs are CD34+/CD38- cells that express distinct profiles of markers and target antigens. Characterization of MCL LSCs should facilitate their purification and should support the development of LSC-eradicating curative treatment approaches in this fatal type of leukemia.

journal_name

Leukemia

journal_title

Leukemia

authors

Eisenwort G,Sadovnik I,Schwaab J,Jawhar M,Keller A,Stefanzl G,Berger D,Blatt K,Hoermann G,Bilban M,Willmann M,Winding C,Sperr WR,Arock M,Rülicke T,Reiter A,Valent P

doi

10.1038/s41375-019-0460-6

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

2673-2684

issue

11

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-019-0460-6

journal_volume

33

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Stromal cell-mediated transcriptional regulation of the CD13/aminopeptidase N gene in leukemic cells.

    abstract::CD13/aminopeptidase N (APN) is a cell surface metallopeptidase expressed by normal and leukemic myeloid cells, and by lymphoblasts in 5-10% of acute lymphoid leukemia (ALL) cases, previously classified as 'biphenotypic' or 'mixed-lineage' leukemias. In fresh cells from two early B-lineage, t(9;22)-positive, ALL cases ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Saito M,Kumagai M,Okazaki T,Nakazawa S,Shapiro LH,Look AT,Campana D

    更新日期:1995-09-01 00:00:00

  • Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.

    abstract::We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients bein...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01031-1

    authors: Largeaud L,Cornillet-Lefebvre P,Hamel JF,Dumas PY,Prade N,Dufrechou S,Plenecassagnes J,Luquet I,Blanchet O,Banos A,Béné MC,Bernard M,Bertoli S,Bonmati C,Fornecker LM,Guièze R,Haddaoui L,Hunault M,Ianotto JC,Jourdan

    更新日期:2020-09-18 00:00:00

  • Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) stu

    abstract::Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach to JAK2-V617F detection, with assays varying markedly in performance, af...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2013.219

    authors: Jovanovic JV,Ivey A,Vannucchi AM,Lippert E,Oppliger Leibundgut E,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G,Guglielmelli P,van der Reijden BA,Jansen JH,Alpermann T,Schnittger S,Bench A,Tobal K,Wilkins B,Cu

    更新日期:2013-10-01 00:00:00

  • Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

    abstract::In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of RQ-PCR and further increase sensitivity, specificity, accuracy and reproducibili...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.375

    authors: Ladetto M,Brüggemann M,Monitillo L,Ferrero S,Pepin F,Drandi D,Barbero D,Palumbo A,Passera R,Boccadoro M,Ritgen M,Gökbuget N,Zheng J,Carlton V,Trautmann H,Faham M,Pott C

    更新日期:2014-06-01 00:00:00

  • A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission.

    abstract::Graft-versus-host disease (GVHD) remains a major immunological complication after allogeneic bone marrow transplantation (allo-BMT), but also favors development of the beneficial graft-versus-leukemia (GVL) effect. A patient with AML-M4 (inv (16)) is described, who was given non-myeloablative remission reinduction the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400810

    authors: Vandenberghe P,Verhoef GE,Emonds MP,Demuynck H,Zachée P,De Wolf-Peeters C,Decorte R,Cassiman JJ,Boogaerts MA

    更新日期:1997-10-01 00:00:00

  • Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

    abstract::This corrects the article DOI: 10.1038/leu.2017.9. ...

    journal_title:Leukemia

    pub_type: 杂志文章,已发布勘误

    doi:10.1038/leu.2017.348

    authors: Schütz C,Inselmann S,Saussele S,Dietz CT,Müller MC,Eigendorff E,Brendel CA,Metzelder SK,Brümmendorf TH,Waller C,Dengler J,Goebeler ME,Herbst R,Freunek G,Hanzel S,Illmer T,Wang Y,Lange T,Finkernagel F,Hehlmann R,Hu

    更新日期:2018-04-01 00:00:00

  • Chloroquine induces basophilic differentiation of HL-60 cells.

    abstract::Many agents have been known to induce the differentiation of HL-60 cells. However, only a small number of reports on the basophilic differentiation of this cell line are known. In this study we show that the exposure of HL-60 cells to chloroquine induces to differentiate into basophils. This chloroquine-induced change...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Sasaki R,Furukawa Y,Okada K,Nakamura M,Yamane Y,Miura Y,Eguchi M

    更新日期:1997-04-01 00:00:00

  • Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.

    abstract::Smoldering multiple myeloma (SMM) is a biologically heterogeneous, clinically defined entity with a variable rate of progression to symptomatic multiple myeloma (MM). Reliable markers for progression are critical for the development of potential therapeutic interventions. We retrospectively evaluated the predictive va...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0013-4

    authors: Fernández de Larrea C,Isola I,Pereira A,Cibeira MT,Magnano L,Tovar N,Rodríguez-Lobato LG,Calvo X,Aróstegui JI,Díaz T,Lozano E,Rozman M,Yagüe J,Bladé J,Rosiñol L

    更新日期:2018-06-01 00:00:00

  • Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.

    abstract::The NUP214-ABL1 fusion kinase has recently been identified in 6% of patients with T-cell acute lymphoblastic leukemia. In contrast to the more common oncogenic ABL1 fusion BCR-ABL1, NUP214-ABL1 localizes to the nuclear pore complexes and has attenuated transforming properties in hematopoietic cells and in mouse bone m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.242

    authors: De Keersmaecker K,Versele M,Cools J,Superti-Furga G,Hantschel O

    更新日期:2008-12-01 00:00:00

  • Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.

    abstract::We evaluated the synergistic activity of AS101 (ammonium trichloro-(dioxoethylene-0-0')-tellurate) with the protein kinase C (PKC) activators, Bryostatin-1 and phorbol-12-myristate-13-acetate (PMA), on human myelocytic leukemia cell differentiation in vitro, and in a mouse model. Use of AS101 with Bryostatin-1 or with...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404746

    authors: Hayun M,Okun E,Hayun R,Gafter U,Albeck M,Longo DL,Sredni B

    更新日期:2007-07-01 00:00:00

  • Establishment and characterization of a murine megakaryoblastic cell line growing in protein-free culture (L8057Y5).

    abstract::A murine megakaryoblastic cell line growing in protein-free culture (L8057Y5) was established from an experimentally induced murine leukemia (MK8057). Most of the Y5 cells were small and blast-like, with 2-4N in DNA content. Also, large cells possessing a lobulated nucleus characteristic of megakaryocytes, which showe...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Sasaki H,Kajigaya Y,Hirabayashi Y,Funabiki T,Inoue T,Yokota T,Ikuta K,Arai K,Matsuyama S

    更新日期:1991-05-01 00:00:00

  • Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.

    abstract::In most cases of lymphomas with blood dissemination, the careful cytological analysis of peripheral blood smears provides a rapid orientation to diagnosis, even if the final subtyping is achieved by histology and eventually other techniques. Here, we evaluated if the analysis of blood smears may suggest the blood diss...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404013

    authors: Baseggio L,Berger F,Morel D,Delfau-Larue MH,Goedert G,Salles G,Magaud JP,Felman P

    更新日期:2006-02-01 00:00:00

  • In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.

    abstract::We report here the case of a 55-year-old patient with chronic granular lymphocyte disorder associated with moderate neutropenia. The majority of peripheral blood lymphocytes displayed a CD3-, CD8-, CD16+, CD56(NKH1)- phenotype. The patient's cells showed high spontaneous cytotoxic activity against K562 targets and dev...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bayle C,Vitté-Mony I,Lang P,Pico J,Hercend T,Bertoglio J

    更新日期:1992-05-01 00:00:00

  • Clinical significance of beta 2-microglobulin in serum of adult T cell leukemia.

    abstract::To clarify the clinical and biological significance of beta 2-microglobulin (beta 2-M) in serum of adult T cell leukemia (ATL) associated with human lymphotropic virus type-I (HTLV-I), beta 2-M was measured in 52 patients with ATL (acute ATL, 35 patients; lymphoma ATL, two patients; chronic ATL, 12 patients; smolderin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Sadamori N,Mine M,Hakariya S,Ichiba M,Kawachi T,Itoyama T,Nakamura H,Tomonaga M,Hayashi K

    更新日期:1995-04-01 00:00:00

  • Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells.

    abstract::Single-colony karyotyping (SCK) and reverse-transcription polymerase chain reaction (RT-PCR) are two increasingly used techniques for the quantification of leukemic colonies generated by chronic myelogenous leukemia (CML) cell fractions purged or selected in vitro. Recently, the existence of Philadelphia (Ph) chromoso...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400942

    authors: Savoldo B,Sammarelli G,Dotti G,Garau D,Regazzi E,Cilloni D,Tabilio A,Rizzoli V,Carlo-Stella C

    更新日期:1998-03-01 00:00:00

  • Biologic response modifiers in acute lymphoblastic leukemia.

    abstract::Despite the presence of tumor antigens, the paucity of clinically significant T-cell mediated immune responses against human tumors is striking. This may, in part, be because of the inability of cancer cells to function as efficient antigen-presenting cells. For full activation, T cells must receive two signals delive...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Gribben JG,Cardoso AA,Schultze JL,Nadler LM

    更新日期:1997-05-01 00:00:00

  • Targeting MYC in multiple myeloma.

    abstract::Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation relates to translocation or gain of the MYC locus and deregulation of upstream pathways such as IRF4, DIS3/LIN28B/...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-018-0036-x

    authors: Jovanović KK,Roche-Lestienne C,Ghobrial IM,Facon T,Quesnel B,Manier S

    更新日期:2018-06-01 00:00:00

  • Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).

    abstract::Acute myeloid leukemia (AML) with 11q23/MLL rearrangement (MLL-r AML) is allocated to the intermediate- or high-risk cytogenetic prognostic category depending on the MLL fusion partner. A more favorable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (alloHSCT), bu...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2015.143

    authors: Pigneux A,Labopin M,Maertens J,Cordonnier C,Volin L,Socié G,Blaise D,Craddock C,Milpied N,Bacher U,Malard F,Esteve J,Nagler A,Mohty M,Acute Leukemia Working Party EBMT.

    更新日期:2015-12-01 00:00:00

  • Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia.

    abstract::Children with acute lymphoblastic leukemia (ALL) with > or = 0.01% leukemic cells in the bone marrow after remission induction are at a greater risk of relapse. The most promising methods of detecting minimal residual disease (MRD) are flow cytometric identification of leukemia-associated immunophenotypes and polymera...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401459

    authors: Neale GA,Coustan-Smith E,Pan Q,Chen X,Gruhn B,Stow P,Behm FG,Pui CH,Campana D

    更新日期:1999-08-01 00:00:00

  • Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.

    abstract::Dasatinib treatment markedly increases the number of large granular lymphocytes (LGLs) in a proportion of Ph+ leukemia patients, which associates with a better prognosis. The lymphocytosis is predominantly observed in cytomegalovirus (CMV)-seropositive patients, yet detectable CMV reactivation exists only in a small f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.174

    authors: Ishiyama K,Kitawaki T,Sugimoto N,Sozu T,Anzai N,Okada M,Nohgawa M,Hatanaka K,Arima N,Ishikawa T,Tabata S,Onaka T,Oka S,Nakabo Y,Amakawa R,Matsui M,Moriguchi T,Takaori-Kondo A,Kadowaki N

    更新日期:2017-01-01 00:00:00

  • Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519).

    abstract::Abnormalities of several cell-cycle regulatory genes including cyclin D1, p16CDKN2 and p15CDKN2B have been described in B cell non-Hodgkin's lymphoma (B-NHL). We describe a new B-NHL cell line (Granta 519), with concurrent abnormalities of the cyclin D1, pl6CDKN2 and pl5CDKN2B genes. An independent clinical case of ma...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400555

    authors: Jadayel DM,Lukas J,Nacheva E,Bartkova J,Stranks G,De Schouwer PJ,Lens D,Bartek J,Dyer MJ,Kruger AR,Catovsky D

    更新日期:1997-01-01 00:00:00

  • Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells.

    abstract::CDCP1, a novel stem cell marker, is expressed in hematopoietic cell line K562 but not in Jurkat. When CDCP1 promoter was transfected exogenously, Jurkat showed comparable promoter activity with K562, suggesting that the factor to enhance transcription was present but interfered to function in Jurkat. The reporter assa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404312

    authors: Kimura H,Morii E,Ikeda JI,Ezoe S,Xu JX,Nakamichi N,Tomita Y,Shibayama H,Kanakura Y,Aozasa K

    更新日期:2006-09-01 00:00:00

  • General Report on the European Union Concerted Action Workshop on 11q23, London, UK, May 1997.

    abstract::Seventeen cytogenetic laboratories in eight European countries contributed karyotypic, hematological, clinical and follow-up data from 550 patients with an acquired abnormality of 11q23. The patients had acute lymphoblastic leukemia (254), acute myeloid leukemia (250), unspecified, undifferentiated, biphenotypic acute...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401011

    authors: Secker-Walker LM

    更新日期:1998-05-01 00:00:00

  • All-trans retinoic acid induces monocyte growth factor receptor (c-fms) gene expression in HL-60 leukemia cells.

    abstract::All-trans-retinoic (ATRA) treatment of patients with acute promyelocytic leukemia results in differentiation of the malignant cells and a high complete remission rate. ATRA treatment induced granulocytic differentiation in HL-60 cells as assessed by nitroblue tetrazolium (NBT) reduction, but had no effect on non-speci...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Hsu HC,Yang K,Kharbanda S,Clinton S,Datta R,Stone RM

    更新日期:1993-03-01 00:00:00

  • Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

    abstract::Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.243

    authors: Teh TC,Nguyen NY,Moujalled DM,Segal D,Pomilio G,Rijal S,Jabbour A,Cummins K,Lackovic K,Blombery P,Thompson E,Ekert PG,Lessene G,Glaser SP,Huang DCS,Roberts AW,Guthridge MA,Wei AH

    更新日期:2018-02-01 00:00:00

  • Allelotype analysis of the myelodysplastic syndrome.

    abstract::Myelodysplastic syndromes (MDS) are a group of clonal hematologic disorders found predominantly in the elderly. The molecular mechanisms underlying the development of MDS remain obscure. In order to begin to identify tumor suppressor genes involved in these disorders, we performed a detailed microsatellite allelotype ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401717

    authors: Xie D,Hofmann WK,Mori N,Miller CW,Hoelzer D,Koeffler HP

    更新日期:2000-05-01 00:00:00

  • Role of cytokines in the treatment of acute leukemias: a review.

    abstract::Myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, have been used to decrease the duration of chemotherapy-induced neutropenia and thereby reduce the incidence and severity of infections in various regimens used to treat acute myeloid leukemia an...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404152

    authors: Ravandi F

    更新日期:2006-04-01 00:00:00

  • Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.

    abstract::The inv(16)(p13q22) chromosomal rearrangement associated with FAB M4Eo acute myeloid leukemia (AML) subtype is characterized by the presence of the CBFbeta/MYH11 fusion transcript that can be used to detect minimal residual disease (MRD). However, qualitative RT-PCR studies of MRD have so far produced conflicting resu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402478

    authors: Guerrasio A,Pilatrino C,De Micheli D,Cilloni D,Serra A,Gottardi E,Parziale A,Marmont F,Diverio D,Divona M,Lo Coco F,Saglio G

    更新日期:2002-06-01 00:00:00

  • Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

    abstract::We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfav...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.234

    authors: Caramazza D,Begna KH,Gangat N,Vaidya R,Siragusa S,Van Dyke DL,Hanson C,Pardanani A,Tefferi A

    更新日期:2011-01-01 00:00:00

  • Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.

    abstract::In B-CLL IgV(H) genes mutational status is a major prognostic factor. Since sequencing of IgV(H) genes is not available in most laboratories, an easily performed surrogate assay is desirable. To identify the best surrogate assay, and to better discriminate prognostic subgroups we analyzed clinical and biological data ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402780

    authors: Magnac C,Porcher R,Davi F,Nataf J,Payelle-Brogard B,Tang RP,Oppezzo P,Lévy V,Dighiero G,Ajchenbaum-Cymbalista F

    更新日期:2003-01-01 00:00:00